Paradigm Biopharmaceuticals (ASX:PAR) Short Percentage of Float


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
28 GF Score
Price A$0.16
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:PAR vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Short Percentage of Float falls into.


ASX:PAR
28GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
28GF Score

Get the complete analysis for ASX:PAR

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price